Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2021

Sep 23, 2021

31100_dirs_2021-09-23_d0c69e33-01ad-479f-b618-1b3d03e05fbc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-09-21

Reporting Person: PICKERING GRANT (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-09-21 Common Stock M 10807 $1.79 Acquired 591061 Direct
2021-09-21 Common Stock S 10005 $25.17 Disposed 581056 Direct
2021-09-21 Common Stock S 802 $25.89 Disposed 580254 Direct
2021-09-22 Common Stock M 4193 $1.79 Acquired 584447 Direct
2021-09-22 Common Stock S 4193 $25.1933 Disposed 580254 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-09-21 Stock Option (right to buy) $1.79 M 10807 Disposed 2027-05-17 Common Stock (10807) Direct
2021-09-22 Stock Option (right to buy) $1.79 M 4193 Disposed 2027-05-17 Common Stock (4193) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 355660 Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.73 to $25.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.88 to $25.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.90 to $25.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: The shares subject to the option are fully vested and exercisable.